Discontinuation of warfarin is unnecessary in total knee arthroplasty
| Autor: | David A. Rhodes, Harold K. Dunn, Erik P. Severson, Jeffrey T. Hodrick, Aaron A. Hofmann |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Blood transfusion medicine.drug_class medicine.medical_treatment Postoperative Hemorrhage Drug Administration Schedule Medicine Humans Orthopedics and Sports Medicine Blood Transfusion Arthroplasty Replacement Knee Aged Retrospective Studies Aged 80 and over business.industry Anticoagulant Warfarin Anticoagulants Retrospective cohort study General Medicine Perioperative Middle Aged Arthroplasty Surgery Discontinuation Regimen Anesthesia Preoperative Period Female Symposium: Papers Presented at the Annual Meetings of the Knee Society business medicine.drug |
| Zdroj: | Clinical orthopaedics and related research. 468(1) |
| ISSN: | 1528-1132 |
| Popis: | Patients with medical comorbidities that necessitate chronic anticoagulation therapy frequently present as candidates for total knee arthroplasty (TKA). We asked whether it was necessary to stop warfarin preoperatively to avoid postoperative bleeding complications. We retrospectively reviewed 77 preoperatively anticoagulated patients undergoing TKA. Thirty-eight of these 77 patients were maintained on their routine therapeutic warfarin regimen throughout the perioperative period. The remaining 39 patients had their routine preoperative warfarin regimen discontinued preoperatively and then restarted after surgery. We compared rates of comorbid illness, blood transfusions, wound complications, and reoperations. The demographic data and the ratio of primary to revision arthroplasties were similar in the two groups. The age-adjusted risk ratios for blood transfusions, wound complications, and reoperations were 0.61, 0.29, and 0.43, respectively. The data presented suggest maintaining a therapeutic warfarin regimen throughout the perioperative period for high-risk patients is not associated with an increase risk of complications after TKA.Level III, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink